Oxytocin antagonists seem to have potential as a treatment option for premature ejaculation (PE), but the parameters of their use are vague. Two recently published studies highlight the need for large-scale trials to elucidate the value of these drugs in the treatment of PE.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saitz, T. R. & Serefoglu, E. C. The epidemiology of premature ejaculation. Transl Androl. Urol. 5, 409–415 (2016).
Saitz, T. R. & Serefoglu, E. C. Advances in understanding and treating premature ejaculation. Nat. Rev. Urol. 12, 629–640 (2015).
Giuliano, F. & Clement, P. Pharmacology for the treatment of premature ejaculation. Pharmacol. Rev. 64, 621–644 (2012).
Veening, J. G. et al. The role of oxytocin in male and female reproductive behavior. Eur. J. Pharmacol. 15, 209–228 (2014).
Shinghal, R. et al. Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. J. Sex. Med. 10, 2506–2517 (2013).
McMahon, C. et al. PD69-01 a phase IIa study to investigate the efficacy and safety of the selective oxytocin receptor antagonist, IX-01, in men with lifelong premature ejaculation. J. Urol. 197, e1344 (2017).
Osterloh, I. H. et al. Pharmacokinetics, safety, and tolerability of single oral doses of a novel oxytocin receptor antagonist-cligosiban-in development for premature ejaculation: three randomized clinical trials in healthy subjects. J. Sex. Med. 15, 1547–1557 (2018).
Wayman, C. et al. Cligosiban, a novel brain-penetrant, selective oxytocin receptor antagonist, inhibits ejaculatory physiology in rodents. J. Sex. Med. 15, 1698–1706 (2018).
McMahon, C. et al. The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient-reported outcomes in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled proof-of-concept trial (PEPIX). J. Sex. Med. 16, 1178–1187 (2019).
Althof, S. et al. The oxytocin antagonist cligosiban fails to prolong intravaginal ejaculatory latency in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled phase IIb trial (PEDRIX). J. Sex. Med. 16, 1188–1198 (2019).
Acknowledgements
M.G. is supported by the European Urological Scholarship Programme (EUSP) for his post-doctoral andrology fellowship training
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Gul, M., Serefoglu, E.C. Oxytocin antagonists: the next frontier in PE treatment. Nat Rev Urol 16, 696–697 (2019). https://doi.org/10.1038/s41585-019-0238-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0238-7
This article is cited by
-
Current and emerging treatment options for premature ejaculation
Nature Reviews Urology (2022)
